Regulatory issues set up pitfalls in the race to Rituxan biosimilars

October 30, 2012 | Analyst Insight

Electronics giant Samsung halted clinical trials for its SAIT101, a biosimilar for Roche's blockbuster Rituxan. Though it did not offer any further explanation, a source close to the company cites...